2[2]Mendel R, Carter LP. Evaluation and treatment of clinical vasospasm following subaraclinoid aneurys,. J Neurosuryg, 1994,16:6-12. 被引量：1
3[3]Shimoda M, Oda S,Tsugane R, et al. Intracranial complications of hypervolemic therapy inpatients with a delayed ischemic deficit attributed to vasospasm. J Neurosurg, 1993,78:423-428. 被引量：1
4[4]Hirashima Y,Endo S,Otsuji T,et al. Platelet-activating factor and cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg, 1993,78:592-599. 被引量：1
5[5]Cammussi G, Aglietta M, Codar, et al. Release of platelet-activating factor (PAF) and histamine Ⅱ .The cellular origin of human PAF:monocytes,polymorphonuclear neutrophils and basophils. lmmunology, 1981,42:191-197. 被引量：1
6[6]Freyssinet JM, WieselML, G auchy J, et al. CazenaveJ-P An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost, 1986,53:309-315. 被引量：1
